Product
Supplier
Encyclopedia
Inquiry

EN

Home > Chemial News > Pharma News > BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors

BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors

ECHEMI 2022-05-13

BridgeBio Pharma announced today that it has entered into an agreement with Bristol-Myers Squibb to co-develop and commercialize a potential "best-in-class" SHP2 inhibitor, BBP-398, in oncology.

 

SHP2 is a protein tyrosine phosphatase that links growth factor, cytokine, and integrin signaling with the downstream RAS/MAPK signaling pathway to regulate cell proliferation and survival. Excessive SHP2 activity is an important factor in the development of various cancers, it is also a mechanism of resistance to various targeted therapies, and it can suppress antitumor immune responses.

 

BBP-398 is a SHP2 inhibitor jointly developed by BridgeBio and MD Anderson Cancer Center. BridgeBio has partnered with Lian Tuo Bio to conduct clinical development and commercialization of BBP-398 in China and other major Asian markets, in combination with other drugs, for the treatment of solid tumors such as non-small cell lung cancer, colorectal cancer and pancreatic cancer.

 

Under the agreement, BridgeBio will continue to lead ongoing Phase 1 clinical trials examining BBP-398 as a single agent or as part of a combination therapy. Bristol-Myers Squibb will lead subsequent development and commercialization activities. BridgeBio will receive an upfront payment of $90 million and is eligible to receive development, regulatory and sales milestone payments of up to $815 million.

 

"We are delighted to expand our collaboration with Bristol-Myers Squibb, which we believe will allow us to reach more difficult-to-treat cancer patients. We believe our SHP2 inhibitors have 'best-in-class' potential. ” said BridgeBio founder and CEO Dr. Neil Kumar.

Share to:
Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Suggestions
Email:
Message:
Send Message